MAPK Pathway Activation in Uveal Melanoma
Author Information
Author(s): W. Zuidervaart, F. van Nieuwpoort, M. Stark, R. Dijkman, L. Packer, A-M. Borgstein, S. Pavey, P. van der Velden, C. Out, M. J. Jager, N. K. Hayward, N. A. Gruis
Primary Institution: Leiden University Medical Centre
Hypothesis
Is the MAPK pathway activated in uveal melanoma through mechanisms different from cutaneous melanoma?
Conclusion
The MAPK pathway is commonly activated in uveal melanoma, but not through mutations in RAS or BRAF genes.
Supporting Evidence
- Only one cell line carried a BRAF mutation, while all primary tumours were wild type for BRAF.
- No mutations were found in the NRAS, HRAS, or KRAS genes.
- Phosphorylated ERK1/2 expression was observed in 10 of 19 tumours despite the lack of mutations.
Takeaway
Uveal melanoma often has a working MAPK pathway, but it doesn't rely on the usual mutations found in other types of melanoma.
Methodology
Mutation analysis of RAS and BRAF genes in 11 uveal melanoma cell lines and 19 primary tumours, along with Western blot and immunohistochemical analyses.
Limitations
The study only analyzed a limited number of cell lines and primary tumours.
Participant Demographics
Caucasian populations, with an annual incidence of 6-8 new cases per million.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website